Gyre Therapeutics/$GYRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gyre Therapeutics
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Ticker
$GYRE
Sector
Health Care
Primary listing
Employees
579
Headquarters
Website
GYRE Metrics
BasicAdvanced
$653M
347.39
$0.02
-
-
Price and volume
Market cap
$653M
52-week high
$19.00
52-week low
$6.11
Average daily volume
129K
Financial strength
Current ratio
3.604
Quick ratio
2.647
Long term debt to equity
0.748
Total debt to equity
1.52
Profitability
EBITDA (TTM)
12.139
Gross margin (TTM)
96.23%
Net profit margin (TTM)
7.20%
Operating margin (TTM)
10.36%
Effective tax rate (TTM)
23.91%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
5.18%
Return on equity (TTM)
12.12%
Valuation
Price to earnings (TTM)
347.39
Price to revenue (TTM)
6.144
Price to book
9.26
Price to tangible book (TTM)
10.01
Price to free cash flow (TTM)
-59.618
Free cash flow yield (TTM)
-1.68%
Free cash flow per share (TTM)
-0.121
Growth
Revenue change (TTM)
-13.01%
Earnings per share change (TTM)
-101.72%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gyre Therapeutics stock?
Gyre Therapeutics (GYRE) has a market cap of $653M as of August 08, 2025.
What is the P/E ratio for Gyre Therapeutics stock?
The price to earnings (P/E) ratio for Gyre Therapeutics (GYRE) stock is 347.39 as of August 08, 2025.
Does Gyre Therapeutics stock pay dividends?
No, Gyre Therapeutics (GYRE) stock does not pay dividends to its shareholders as of August 08, 2025.
When is the next Gyre Therapeutics dividend payment date?
Gyre Therapeutics (GYRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Gyre Therapeutics?
Gyre Therapeutics (GYRE) does not currently have a Beta indicator.